Clinical and Experimental Vaccine Research

The Korean Vaccine Society (대한백신학회)
권호 표지
DOI QR코드

DOI QR Code

Intranasal and intraperitoneal immunization against Brucella infection using niosome and mannosylated niosomes containing Brucella recombinant trigger factor/Bp26/Omp31 chimeric protein in a mouse model

  • Fahimeh Sharif (Department of Microbiology, Islamic Azad University Qom Branch) ;
  • Razieh Nazari (Department of Microbiology, Islamic Azad University Qom Branch) ;
  • Mahdi Fasihi-Ramandi (Molecular Biology Research Center, Baqiyatallah University of Medical Sciences) ;
  • Ramezan Ali Taheri (Nanobiotechnology Research Center, Baqiyatallah University of Medical Sciences) ;
  • Mohsen Zargar (Department of Microbiology, Islamic Azad University Qom Branch)
  • Received : 2024.02.19
  • Accepted : 2024.06.29
  • Published : 2024.07.31
Download PDF
⟨ Previous Next ⟩

Abstract

Purpose: Brucellosis, a zoonotic infectious disease, is a worldwide health issue affecting animals and humans. No effective human vaccine and the complications caused by the use of animal vaccines are among the factors that have prevented the eradication of the disease worldwide. However, bio-engineering technologies have paved the way for designing new targeted and highly efficacious vaccines. In this regard, the study aimed to evaluate immunity induced by mannosylated niosome containing Brucella recombinant trigger factor/Bp26/Omp31 (rTBO) chimeric protein in a mouse model. Materials and Methods: rTBO as chimeric antigen (Ag) was expressed in Escherichia coli BL21 (DE3) and, after purification, loaded on niosome and mannosylated niosome. The characteristics of the nanoparticles were assessed. The mice were immunized using rTBO, niosome, and mannosylated niosome-rTBO in intranasal and intraperitoneal routes. Serum antibodies (immunoglobulin [Ig]A, IgG, IgG1, and IgG2a) and splenocyte cytokines (interferon-gamma, interleukin [IL]-4, and IL-12) were evaluated in immunized mice. Finally, immunized mice were challenged by B. melitensis and B. abortus. A high antibody level was produced by niosomal antigen (Nio-Ag) and mannosylated noisomal antigen (Nio-Man-Ag) compared to the control after 10, 24, and 38 days of immunization. The IgG2a/IgG1 titer ratio for Nio-Man-Ag was 1.2 and 1.1 in intraperitoneal and intranasal methods and lower than one in free Ag and Nio-Ag. Cytokine production was significantly higher in the immunized animal with Ag-loaded nanoparticles than in the negative control group (p<0.05). Moreover, cytokine and antibody levels were significantly higher in the injection than in the inhalation method (p<0.05). Results: The combination of mannosylated noisome and rTBO chimeric proteins stimulate the cellular and humoral immune response and produce cytokines, playing a role in developing the protective acquired immune response in the Brucella infectious model. Also, the intraperitoneal route resulted in a successful enhancement of cytokines production more than intranasal administration. Conclusion: Designing an effective vaccine candidate against Brucella that selectively induces cellular and humoral immune response can be done by selecting a suitable nanoniosome formulation as an immunoadjuvant and recombinant protein as an immune response-stimulating Ag.

Keywords

Acknowledgement

Thanks to guidance and advice from the "Clinical Research Development Unit of Baqiyatallah Hospital" and the officials of the laboratories of Qom Islamic Azad University.

References

  1. Pappas G, Papadimitriou P, Akritidis N, Christou L, Tsianos EV. The new global map of human brucellosis. Lancet Infect Dis 2006;6:91-9.
  2. Corbel MJ, Elberg SS, Cosivi O. Brucellosis in humans and animals. Geneva: World Health Organization; 2006.
  3. Al-Tawfiq JA. Therapeutic options for human brucellosis. Expert Rev Anti Infect Ther 2008;6:109-20.
  4. Alavi SM, Alavi L. Treatment of brucellosis: a systematic review of studies in recent twenty years. Caspian J Intern Med 2013;4:636-41.
  5. Gee JE, De BK, Levett PN, Whitney AM, Novak RT, Popovic T. Use of 16S rRNA gene sequencing for rapid confirmatory identification of Brucella isolates. J Clin Microbiol 2004;42:3649-54.
  6. Korle SL. The design, construction, and testing of a recombinant DNA vaccine for Brucella abortus and Brucella melitensis [dissertation]. Baton Rouge (LA): Louisiana State University and Agricultural & Mechanical College; 2022.
  7. Hoover DL, Borschel RH. Medical protection against brucellosis. In: Lindler LE, Lebeda FJ, Korch GW, editors. Biological weapons defense: infectious disease. Totowa (NJ): Humana Press; 2005. p. 155-84.
  8. Hou H, Liu X, Peng Q. The advances in brucellosis vaccines. Vaccine 2019;37:3981-8.
  9. Eshtiaghi S, Nazari R, Fasihi-Ramandi M. In-silico and in-vitro evaluation of antibacterial, cytotoxic, and apoptotic activity and structure of modified CM11 peptide. Int J Pept Res Ther 2021;27:1069-78.
  10. Heidary M, Dashtbin S, Ghanavati R, et al. Evaluation of brucellosis vaccines: a comprehensive review. Front Vet Sci 2022;9:925773.
  11. Hop HT, Arayan LT, Huy TX, et al. Immunization of BALB/c mice with a combination of four recombinant Brucella abortus proteins, AspC, Dps, InpB and Ndk, confers a marked protection against a virulent strain of Brucella abortus. Vaccine 2018;36:3027-33.
  12. Zhu L, Wang Q, Wang Y, et al. Comparison of immune effects between Brucella recombinant Omp10-Omp28-L7/L12 proteins expressed in eukaryotic and prokaryotic systems. Front Vet Sci 2020;7:576.
  13. Conacher M, Alexander J, Brewer JM. Niosomes as immunological adjuvants. In: Uchegbu LF, editor. Synthetic surfactant vesicles. London: CRC Press; 2000. p. 219-42.
  14. Shilpa S, Srinivasan BP, Chauhan M. Niosomes as vesicular carriers for delivery of proteins and biologicals. Int J Drug Deliv 2011;3:14-24.
  15. Sankhyan A, Pawar P. Recent trends in niosome as vesicular drug delivery system. J Appl Pharm Sci 2012;2:20-32.
  16. Pardakhty A, Moazeni E. Nano-niosomes in drug, vaccine and gene delivery: a rapid overview. Nanomed J 2013;1:1-12.
  17. Irache JM, Salman HH, Gamazo C, Espuelas S. Mannose-targeted systems for the delivery of therapeutics. Expert Opin Drug Deliv 2008;5:703-24.
  18. Hatami E, Mu Y, Shields DN, et al. Mannose-decorated hybrid nanoparticles for enhanced macrophage targeting. Biochem Biophys Rep 2019;17:197-207.
  19. Mosaiab T, Farr DC, Kiefel MJ, Houston TA. Carbohydrate-based nanocarriers and their application to target macrophages and deliver antimicrobial agents. Adv Drug Deliv Rev 2019;151-152:94-129.
  20. Baillie AJ, Florence AT, Hume LR, Muirhead GT, Rogerson A. The preparation and properties of niosomes: non-ionic surfactant vesicles. J Pharm Pharmacol 1985;37:863-8.
  21. Fasihi-Ramandi M, Ghobadi-Ghadikolaee H, Ahmadi-Renani S, Taheri RA, Ahmadi K. Vibrio cholerae lipopolysaccharide loaded chitosan nanoparticle could save life by induction of specific immunoglobulin isotype. ArtifCells Nanomed Biotechnol 2018;46:56-61.
  22. Gao H, Goncalves C, Gallego T, et al. Comparative binding and uptake of liposomes decorated with mannose oligosaccharides by cells expressing the mannose receptor or DC-SIGN. Carbohydr Res 2020;487:107877.
  23. Xing L, Fan YT, Zhou TJ, et al. Chemical modification of chitosan for efficient vaccine delivery. Molecules 2018;23:229.
  24. Lee SG, Yum JS, Moon HM, et al. Analysis of mannose-binding lectin 2 (MBL2) genotype and the serum protein levels in the Korean population. Mol Immunol 2005;42:969-77.
  25. Jain S, Vyas SP. Mannosylated niosomes as carrier adjuvant system for topical immunization. J Pharm Pharmacol 2005;57:1177-84.
  26. Yang R, Xu J, Xu L, et al. Cancer cell membrane-coated adjuvant nanoparticles with mannose modification for effective anticancer vaccination. ACS Nano 2018;12:5121-9.
  27. Hattori Y, Kawakami S, Suzuki S, Yamashita F, Hashida M. Enhancement of immune responses by DNA vaccination through targeted gene delivery using mannosylated cationic liposome formulations following intravenous administration in mice. Biochem Biophys Res Commun 2004;317:992-9.
  28. Morokata T, Ishikawa J, Yamada T. Antigen dose defines T helper 1 and T helper 2 responses in the lungs of C57BL/6 and BALB/c mice independently of splenic responses. Immunol Lett 2000;72:119-26.
  29. Singh P, Prabakaran D, Jain S, Mishra V, Jaganathan KS, Vyas SP. Cholera toxin B subunit conjugated bile salt stabilized vesicles (bilosomes) for oral immunization. Int J Pharm 2004;278:379-90.
  30. Jain S, Singh P, Mishra V, Vyas SP. Mannosylated niosomes as adjuvant-carrier system for oral genetic immunization against hepatitis B. Immunol Lett 2005;101:41-9.
  31. Lam JS, Mansour MK, Specht CA, Levitz SM. A model vaccine exploiting fungal mannosylation to increase antigen immunogenicity. J Immunol 2005;175:7496-503.
  32. Nian X, Zhang J, Huang S, Duan K, Li X, Yang X. Development of nasal vaccines and the associated challenges. Pharmaceutics 2022;14:1983.
  33. Mohamed Fawzi E, Cruz Bustos T, Gomez Samblas M, et al. Intranasal immunization of lambs with serine/threonine phosphatase 2A against gastrointestinal nematodes. Clin Vaccine Immunol 2013;20:1352-9.
  34. Rebelatto MC, Siger L, Hogenesch H. Kinetics and type of immune response following intranasal and subcutaneous immunisation of calves. Res Vet Sci 2001;71:9-15.
  35. Yang X, Walters N, Robison A, Trunkle T, Pascual DW. Nasal immunization with recombinant Brucella melitensis bp26 and trigger factor with cholera toxin reduces B. melitensis colonization. Vaccine 2007;25:2261-8.
  36. Tabynov K, Sansyzbay A, Kydyrbayev Z, et al. Influenza viral vectors expressing the Brucella OMP16 or L7/L12 proteins as vaccines against B. abortus infection. Virol J 2014;11:69.
  37. Clapp B, Yang X, Thornburg T, Walters N, Pascual DW. Nasal vaccination stimulates CD8(+) T cells for potent protection against mucosal Brucella melitensis challenge. Immunol Cell Biol 2016;94:496-508.